On Wednesday, Shares of Intel Corporation (NASDAQ:INTC), gained 2.80% to $28.60.
Intel® Security released its McAfee Labs Threats Report: August 2015, which comprises a critique of graphics processing unit (GPU) malware claims, an investigation of the top cybercriminal exfiltration techniques, and a five-year retrospective on the evolution of the threat landscape since Intel Corporation’s declaration of the McAfee acquisition.
McAfee Labs commemorates the five-year anniversary of the Intel-McAfee union by comparing what researchers thought would happen starting in 2010 with what actually happened in the realm of hardware and software security threats. Key researchers and executives reviewed our predictions on the security capabilities of silicon, the challenges of emerging hard-to-detect attacks, and our 2010 expectations for new device types as compared to the reality of the marketplace.
The five-year threat landscape analysis suggests:
- Intel Security foresaw threats targeting hardware and firmware components and threatening runtime integrity
- Increasingly evasive malware and long-running attacks did not surprise us but some of the specific tactics and techniques were unimagined five years ago
- Although the volume of mobile devices has raised even faster than we predictable, serious broad-based attacks on those devices has grown much more slowly than we thought
- We are seeing just the starting of attacks and breaches against IoT devices
- Cloud adoption has changed the nature of some attacks, as devices are attacked not for the small amount of data that they store, but as a path to where the important data resides
- Cybercrime has grown into a full-fledged industry with suppliers, markets, service providers, financing, trading systems and a proliferation of business models
- Businesses and consumers still do not pay sufficient attention to updates, patches, password security, security alerts, default configurations, and other easy but critical ways to secure cyber and physical assets
- The discovery and exploitation of core Internet vulnerabilities has demonstrated how some foundational technologies are underfunded and understaffed
- There is growing, positive partnership between the security industry, academia, law enforcement and governments to take down cybercriminal operations
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
Shares of Trevena, Inc. (NASDAQ:TRVN), inclined 25.85% to $11.44, during its last trading session, hitting its highest level.
Trevena declared positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events.
“The data from this trial showed that TRV130, when given on-demand, matched morphine efficacy for pain relief with a markedly improved safety and tolerability profile,” said Neil Singla, M.D., chief scientific officer of Lotus Clinical Research and lead investigator of the study. “The challenges of safely and adequately titrating morphine are well recognized, and these data suggest that, if approved, TRV130 may provide a better option than presently available opioid analgesics.”
In the trial, two regimens of TRV130 were tested: the first comprised of a 1.5 mg intravenous loading dose with 0.1 mg self-administered on-demand doses as often as every 6 minutes (together referred to here as “TRV130 0.1 mg”) using a patient controlled analgesia (PCA) device; the second compriseed of a 1.5 mg loading dose with 0.35 mg on-demand doses (together referred to here as “TRV130 0.35 mg”) using a PCA device. A commonly used morphine PCA regimen was also tested, comprising of a 4 mg loading dose with 1 mg on-demand doses. Placebo was administered as a loading dose and on-demand doses that were volume-matched to the active regimens.
Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline comprises TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain.
Finally, Cenovus Energy Inc. (NYSE:CVE), ended its last trade with 0.15% gain, and closed at $13.50.
Cenovus Energy has closed its formerly declared purchase of Canexus Corporation’s North American Terminal Operations (NATO), a crude-by-rail trans-loading facility in central Alberta. The acquisition is part of Cenovus’s strategy to build a strong portfolio of transportation options to assist maximize market access and capture global prices for its oil.
The company is also happy to declare it has contracted Savage to work with Cenovus’s on-site administration team in the day-to-day operations of the renamed Bruderheim Energy Terminal. Savage is a leading provider of rail transportation and terminal operations in the U.S. and Canada.
Cenovus Energy Inc., an integrated oil company, develops produces, and markets crude oil, natural gas liquids (NGLs), and natural gas in Canada with refining operations in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
